Results 131 to 140 of about 19,152,238 (244)
, 2020 3'-Phosphoinositide-dependent-Kinase-1 (PDK1) is a master regulator whereby its PI3-kinase-dependent dysregulation in human pathologies is well documented.
Jose Requejo-Isidro (1641598) +5 more
core
Prevention of Early Onset of Breast Cancer With Ashwagandha
Molecular Carcinogenesis, EarlyView.ABSTRACT Prevention of breast cancer is feasible because many risk factors for this malignancy are known (e.g., family history, reproductive factors, etc.). Medicinal plants and/or their bioactive phytochemicals are attractive for the prevention of early onset of breast cancer due to their generally favorable safety profile.
Eun‐Ryeong Hahm +2 more
wiley +1 more source
Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry. [PDF]
Biochem J, 2017 Masson GR, Maslen SL, Williams RL.
europepmc +1 more source
Med Research, EarlyView.This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng +14 more
wiley +1 more source
European Respiratory Review, 2005 No currently available treatments reduce the progression or suppress the inflammation of chronic obstructive pulmonary disease (COPD). However, with a better understanding of the inflammatory and destructive process, several targets have been identified,
P. J. Barnes
doaj
Medicinal Research Reviews, EarlyView.ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu +2 more
wiley +1 more source
Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
Medicinal Research Reviews, EarlyView.ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek +3 more
wiley +1 more source
Senotherapeutics for Knee Osteoarthritis
Medicinal Research Reviews, EarlyView.ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman +6 more
wiley +1 more source
, 2007 This thesis is focused on the characterization of new protein kinases from plants. Here, I show that the Arabidopsis UbDK[gamma]4 and UbDK[gamma]7 (ubiquitin-like domain kinases), which were originally identified as putative phosphatidylinositol 4 ...
Galvao, Rafaelo Marques
core
Neuroprotection, EarlyView.Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu +7 more
wiley +1 more source